Stay updated on Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial page.

Latest updates to the Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe site now shows revision v3.4.2, and the previous funding-status notice and revision v3.4.1 have been removed.SummaryDifference0.5%

- Check21 days agoChange DetectedA site-wide status notice about government funding and the NIH Clinical Center being open, along with a software revision tag (v3.4.1), was added. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedUI/text updates include a new Show glossary label and capitalization changes to the QC criteria update entry, along with a new Revision: v3.4.0. The deletions remove the older 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' references.SummaryDifference0.2%

- Check42 days agoChange DetectedThe only visible change is the site revision label updating from v3.3.3 to v3.3.4; no study information or page content was altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a Locations section with Kangnam as a recruitment site. The previous Kangnam Locations entry is removed and the page revision is updated to v3.3.3.SummaryDifference0.2%

- Check92 days agoChange DetectedThe Publications note was updated to say items are automatically filled from PubMed, and a new revision tag v3.3.2 was added (replacing v3.2.0).SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Solid/Micropapillary Lung Adeno Clinical Trial page.